Prevention of Brain Metastasis by Inhibition of Angiogenesis?
Department of Medicine I, Clinical Division of
Oncology, Medical University of Vienna,
Comprehensive Cancer Center, Vienna, Austria
Neurology Clinic & National Center for Tumor
Diseases, Ruprecht-Karls University , Clinical
Cooperation Unit Neurooncology, German Cancer
Research Center (DKFZ), Heidelberg, Germany
Prof. Dr. Frank Winkler,
Neurology Clinic and National Center for Tumor
Diseases, University Hospital Heidelberg &
German Cancer Research Center, Im Neuenheimer
Feld, D-69120 Heidelberg, Germany; phone:
00496221567107; fax: 00496221567554;
Brain metastasis (BM) is frequently observed in distinct tumor entities, including nonsquamous non-small-cell lung cancer (nsNSCLC, mainly lung adenocarcinoma) and triple negative and human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (mBC)1. Lung cancer patients show by far the highest risk to develop BM during their disease: a current populationbased study demonstrated that 20%of all lung cancer patients will develop BM, compared with 6.5%of renal carcinoma, 6.9%of melanoma, and 5.1%of breast carcinoma
patients2. Given its high incidence, lung cancer is therefore responsible for about 60%of all BM2.